Phase 1 data shows sabirnetug (ACU193) is safe, reduces amyloid plaques, and supports ongoing Phase 2 trial for early Alzheimer’s disease. The press release implies that while there were positive ...

CEO Dan O'Connell reported that Acumen completed enrollment of its 542-participant Phase 2 ALTITUDE-AD study evaluating Sabirnetug for early Alzheimer’s disease, stating, "We completed enrollment of ...

HOUSTON—The Ad Astra Rocket Co. has completed a 30-month NASA contract to continue advancing its Variable Specific Impulse Magnetoplasma Rocket (VASIMR) concept with the potential to reach Mars within ...

Spyrosoft Group, a leading consulting and software development company, is proud to announce the launch of Spyrosoft Ad tech, a new entity focused on building custom advertising and marketing software ...

NEW YORK, Sept. 4, 2025 /PRNewswire/ -- The Ad Council, America's leader in using the power of communications to drive social impact at scale, announced today that Jennifer Mamlet is joining the ...